bearish
Sosei Group (4565 JP): Hit Hard by Partner’s Clinical Trial Termination; Need Time to Recover
411 Views30 Jun 2023 15:47
SUMMARY
- Sosei Group (4565 JP) shares sold off heavily after a major setback in partner’s clinical trial. On June 26, Pfizer Inc (PFE US) decided to discontinue the development of lotiglipron (PF-07081532).
- PF-07081532 is one of three clinical candidates nominated by Pfizer during its multi-target drug discovery collaboration with Sosei to research and develop potential new medicines.
- As lotiglipron was the most advanced clinical candidate using Sosei’s drug discovery platform, the heavy sell-off seen in Sosei shares should not be considered as overreaction.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Sosei Group (4565 JP): Hit Hard by Partner’s Clinical Trial Termination; Need Time to Recover30 Jun 2023
- Sosei Group (4565 JP) TSE Prime Promotion and TOPIX Inclusion... Finally08 Mar 2023
- Sosei Group (4565 JP): Partners’ Pipeline Progress Reflects Power of Drug Discovery Platform18 Jan 2023
- Autonomous Driving- Are We There Yet?20 Mar 2018
x